About Advaxis

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: re

Company Highlights
Year Founded

2002

icon-altStatus

Acquired

icon-altEmployees

43

Location (HQ)

USA

Since Last Funding

2 years 7 months

Monthly Website Visitors

484

icon-altTotal Investment Amt

$200M

Last Funding Round

Post Ipo Equity

icon-altMoM Headcount Growth

-6.51%

icon-altYoY Headcount Growth

-4.43%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Pharmaceutical

Biotechnology

Health Diagnostics